Bio2 Technologies raises $4.3M for Vitrium clinical trial

Bio2 Technologies raised $4.3 million for Vitrium, its resorbable orthopedic biomaterial for musculoskeletal surgery, reports Mass Device.

Advertisement

Three things to know:

1. Vitrium enables surgeons to reconstruct bony anatomy and is currently undergoing a clinical trial.

2 The device consists of bioactive glass and features porous, load-bearing and osteoconductive properties.

3. In August, Bio2 enrolled its first index patient in its Vitrium cervical interbody trial and aims to enroll up to 168 participants to compare the cervical implant to allograft.

More articles on devices:
‘A dream come true’: Dr. Jorge Chahla strives for success at Rush
New York hospital invests $2M in imaging system for spine, brain — 4 things to know
What Stryker’s spine division stands to gain from 5 acquisitions 

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

160 ambulatory leaders just ranked the EHR as the single system most overdue for AI reinvention

Tuesday, August 11
12:00 PM - 1:00 PM CDT

Presenter: Gautam Shah, MBA, FACHDM, NextGen Healthcare

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.